21917-76-0

Usage

Uses

Used in Pharmaceutical Industry:
2-METHYL-1,3-THIAZOLE-4-CARBONITRILE is used as a key intermediate in the synthesis of various drug molecules for its ability to contribute to the development of new therapeutic agents. Its presence in the molecular structure of drugs can enhance their biological activities and therapeutic effects.
Used in Agrochemical Industry:
2-METHYL-1,3-THIAZOLE-4-CARBONITRILE is used as a building block in the creation of agrochemicals, particularly for its potential to improve the effectiveness of pesticides and other agricultural chemicals. Its incorporation can lead to the development of more efficient and targeted agrochemical products.
Used in Organic Synthesis:
2-METHYL-1,3-THIAZOLE-4-CARBONITRILE is utilized as a versatile component in organic synthesis, allowing for the creation of a wide range of organic compounds with various applications. Its unique structure and properties make it a valuable asset in the synthesis of complex organic molecules.
Used in Antimicrobial Applications:
Due to its antibacterial, antifungal, and antiviral properties, 2-METHYL-1,3-THIAZOLE-4-CARBONITRILE is used as an active ingredient in antimicrobial formulations. It can be incorporated into various products to prevent the growth of harmful microorganisms and protect against infections.

InChI:InChI=1/C5H4N2S/c1-4-7-5(2-6)3-8-4/h3H,1H3

Upstream product

• 6436-59-5 ethyl 2-methylthiazole-4-carboxylate 
• 62893-19-0 cefoperazone 

Downstream Products

• 454483-81-9 2-(bromomethyl)-1,3-thiazole-4-carbonitrile 
• 302341-70-4 2-(aminomethyl)-thiazole-4-carbonitrile 
• 298205-14-8 2,5-dimethyl-1-[[4-[2-(2-methyl-4-thiazolyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]-1H-pyrrole 
• 298205-13-7 1-[[-[4,5-dihydro-4-hydroxy-2-(2-methyl-4-thiazol)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]-2,5-dimethyl-1H-pyrrole 
• 848555-07-7 5-[hydroxy-(2-nitrophenyl)methyl]-2-methylthiazole-4-carbonitrile 
• 1221430-83-6 6-benzyl-2-(2-methyl-thiazol-4-yl)thieno[2,3-d]pyrimidin-4-ylamine 

Relevant academic research and scientific papers

Zeolite 4A supported CdS/g-C3N4 type-II heterojunction: A novel visible-light-active ternary nanocomposite for potential photocatalytic degradation of cefoperazone

The CdS/g-C3N4 heterojunction photocatalyst supported on 4A zeolite was successfully synthesized using a simple chemical precipitation method. The physicochemical characteristics of the as-prepared ternary composite were assessed using X-Ray diffraction (XRD), field emission- scanning electron microscopy (FE-SEM), energy dispersive X-Ray (EDX), transmission electron microscopy (TEM), N2 adsorption–desorption, differential reflectance spectroscopy (UV–Vis-DRS), and photoluminescence (PL) techniques. The results confirmed the successful synthesis of the CdS/g-C3N4/4AZ nanocomposite and introduction of the CdS and g-C3N4 on the substrate of 4A zeolite. Cefoperazone (CFP) antibiotic was tested as the model pollutant to assess the photocatalytic performance of the synthesized nanocomposite under visible light irradiation. The response surface methodology (RSM) and artificial neural network (ANN) showed desirable reasonability for the prediction of the CFP degradation efficiency. More than 93% of CFP with a concentration of 17 mg L-1 degraded in the presence of the 0.4 g L-1 of the catalyst at pH of 9 after 80 min treatment time (RSM-based optimization results). The pH of the solution, irradiation time, catalyst dosage, and the initial concentration of the CFP affected degradation efficiency with a percentage impact of 37, 29, 19, and 15 %, respectively (ANN-based modeling results). The addition of 1 mM of isopropanol, benzoquinone, and sodium oxalate reduced the CFP degradation efficiency from 93.23% to 85.18, 41.16, and 32.47%, respectively, proving the decisive role of the °O2– and h+ in the photodegradation process. The kinetic studies indicated the following of the process from the Langmuir-Hinshelwood's pseudo-first-order model (kapp = 3.71 × 10-2 min?1). The structure of the identified by-products using GC-MS analysis confirmed that CFP mainly decomposed through the cleavage of C-S, C-N, and N-N bonds. Moreover, the formation of the aliphatic compounds and carboxylic acids as by-products confirmed nearly complete mineralization of the CFP to non-toxic products.

INHIBITORS OF BETA-SECRETASE

The present invention relates to compounds represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-monocyclic arginine surrogates

Investigations on P2-P3-heterocyclic dipeptide surrogates directed towards identification of an orally bioavailable thrombin inhibitor led us to pursue novel classes of achiral, non-covalent P1-arginine derivatives. The design, synthesis, and biological activity of inhibitors NC1-NC30 that feature three classes of monocyclic P1-arginine surrogates will be disclosed: (1) (hetero)aromatic amidines, amines and hydroxyamidines, (2) 2-aminopyrazines, and (3) 2-aminopyrimidines and 2-aminotetrahydropyrimidines.